Which drug companies run their trials late?
Every active industry trial registered over a year ago, with its planned readout date today compared with the one it first registered. 5,378 trials qualify.
Listed companies
Companies with at least 30 qualifying trials, ranked by how often they run 6+ months late. Click a company to see its trials on the map.
| # | Company | Trials | Late 6+ mo | On time | Median delay |
|---|---|---|---|---|---|
| 1 | Pfizer $PFE | 93 | 55% | 32% | +22 mo |
| 2 | Gilead Sciences $GILD | 52 | 54% | 42% | +31 mo |
| 3 | Amgen $AMGN | 52 | 54% | 31% | +29 mo |
| 4 | Hoffmann-La Roche $RO.SW | 126 | 48% | 40% | +25 mo |
| 5 | AstraZeneca $AZN | 253 | 47% | 40% | +20 mo |
| 6 | Regeneron Pharmaceuticals $REGN | 58 | 47% | 36% | +23 mo |
| 7 | AbbVie $ABBV | 105 | 46% | 47% | +33 mo |
| 8 | Daiichi Sankyo $4568.T | 33 | 42% | 52% | +24 mo |
| 9 | Novartis Pharmaceuticals $NVS | 142 | 42% | 41% | +30 mo |
| 10 | Akeso $9926.HK | 40 | 40% | 57% | +29 mo |
| 11 | Janssen Research & Development, LLC $JNJ | 98 | 40% | 52% | +25 mo |
| 12 | Eli Lilly and Company $LLY | 104 | 38% | 50% | +17 mo |
| 13 | Bristol-Myers Squibb $BMY | 92 | 38% | 53% | +23 mo |
| 14 | Takeda $TAK | 50 | 38% | 56% | +33 mo |
| 15 | Sanofi $SNY | 87 | 38% | 52% | +20 mo |
| 16 | GlaxoSmithKline $GSK | 86 | 36% | 50% | +13 mo |
| 17 | Merck Sharp & Dohme LLC $MRK | 144 | 31% | 61% | +18 mo |
| 18 | Jiangsu HengRui Medicine Co., Ltd. $600276.SS | 46 | 30% | 61% | +24 mo |
| 19 | Incyte Corporation $INCY | 33 | 30% | 64% | +20 mo |
| 20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. $1177.HK | 43 | 21% | 74% | +15 mo |
By disease area
| Area | Trials | Late 6+ mo | Median delay |
|---|---|---|---|
| Rare | 373 | 56% | +22 mo |
| Eye | 129 | 50% | +29 mo |
| Oncology | 2,551 | 49% | +26 mo |
| GI·Renal·Heme | 303 | 46% | +27 mo |
| Neuro | 451 | 45% | +25 mo |
| Respiratory | 140 | 43% | +15 mo |
| Infectious | 307 | 41% | +24 mo |
| Other | 228 | 41% | +22 mo |
| Immuno | 381 | 40% | +20 mo |
| Cardio-Met | 515 | 39% | +18 mo |
Most-delayed active Phase 3 trials
Largest gap between the first-registered and current primary completion date.
| Trial | First planned | Now | Delay |
|---|---|---|---|
| XePOHCAS Invero Pharma, Inc. · Cardio-Met |
2019-07 | 2029-04 | +117 mo |
| ALLELE Pierre Fabre Medicament · Infectious |
2020-11 | 2030-05-31 | +115 mo |
| CM-AT Curemark · Neuro |
2018-10 | 2028-01 | +111 mo |
| UX111 Ultragenyx Pharmaceutical Inc $RARE · Rare |
2019-12 | 2029-03 | +111 mo |
| Masitinib (6.0) AB Science · Neuro |
2018-09-01 | 2027-12 | +111 mo |
| Elenestinib Blueprint Medicines Corporation · Oncology |
2023-08 | 2032-09-30 | +110 mo |
| PEDZ-K AstraZeneca $AZN · Cardio-Met |
2021-01-07 | 2030-02-21 | +109 mo |
| EPCORE™FL-2 Genmab $GMAB · Oncology |
2028-10-05 | 2037-11 | +109 mo |
| PrTK03 Candel Therapeutics, Inc. · Oncology |
2015-09 | 2024-08 | +107 mo |
| FORTIFY AbbVie $ABBV · GI·Renal·Heme |
2020-04-15 | 2029-02 | +106 mo |
| Cellgram-LC Pharmicell Co., Ltd. · GI·Renal·Heme |
2021-03-02 | 2029-12-01 | +105 mo |
| JR-141 JCR Pharmaceuticals Co., Ltd. · Rare |
2021-06-30 | 2030-03-31 | +105 mo |
| Ublituximab TG Therapeutics, Inc. · Neuro |
2023-10 | 2032-05-31 | +104 mo |
| U-ENDURE AbbVie $ABBV · GI·Renal·Heme |
2019-01-30 | 2027-09 | +103 mo |
| Seladelpar 5 mg Capsule Gilead Sciences $GILD · GI·Renal·Heme |
2020-12 | 2028-11 | +95 mo |
How this is calculated
Source: ClinicalTrials.gov, including each record's version history (the first registered version gives the original plan). Included: industry-sponsored trials that are recruiting, active or not yet recruiting, first registered at least 12 months ago. Excluded: records not updated for a long time (likely out of date), and changes of more than 10 years (almost always a re-used or abandoned record). "Late" means the primary completion date moved back more than 6 months; "on time" means within one month of the original.
Dates are self-reported by sponsors. A delay can reflect slower recruitment, a protocol change, a larger study or simply admin, so it says nothing on its own about whether a drug works. Information only, not investment or medical advice.